The Solid Tumor team at Knight Diagnostic Laboratories performs diagnostic and clinically actionable tests developed at Oregon Health and Science University. The department includes a variety of platforms which allow testing to be performed using the most appropriate technology. Our mass spectroscopy-based solid tumor panel (SequenomR platform) covers 643 mutations across 53 genes known to be important in cancer, one of the largest cancer gene mutation panels available in the U.S.A. In addition, we have recently introduced our GeneTrailsTM 38 Cancer Gene Panel, Non Small Cell Lung Cancer Panel, and Gastro Intestinal Stromal Tumor Panel using next generation technology. More custom panels are in development and will be clinically available in the near future.

Targeted panels are available for the following tumor types:

Colorectal Cancer:

  • Multiplex Solid Tumor panel, including KRAS, BRAF, PIK3CA and CTNNB1
  • Microsatellite instability
  • Mismatch Repair Protein Expression by IHC (for MLH1, MSH2, MSH6, PMS2)
  • Lynch Syndrome Sequencing panel (MLH1, MSH2, MSH6)

Non-Small Cell Lung Cancer:

  • EGFR
  • ALK translocation (FDA-approved FISH probe)
  • Multiplex Solid Tumor Panel, including KRAS, ERBB2/HER2, BRAF, PIK3CA, CTNNB1 and NTRK genes
  • ROS1 (FISH)
  • RET (FISH)

Malignant Melanoma:

  • BRAF
  • NRAS
  • cKIT
  • GNAQ & GNA11 (ocular melanoma)

GI Stromal Tumor (GIST):

  • cKIT with reflex to PDGFRA
  • BRAF (for wild-type GIST)

Breast Cancer:

  • HER2 (FISH)
  • PTEN (IHC)
  • PIK3CA
  • AKT1

Gastric Cancer:

  • HER2 (FISH)

Endometrial Cancer (Endometrioid type):

  • PIK3CA
  • PTEN (IHC)
  • Multiplex solid tumor panel, including PIK3CA, RAS genes, BRAF, CTNNB1


  • MGMT methylation
  • IDH1&IDH2

Bladder Cancer:

  • FGFR3

Thymic Carcinoma:

  • cKIT